EUVIMEDEUVIMED entdecken
Crossref

A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies

Robert L Atmar iD, Khalil Ettayebi iD, Sasirekha Ramani iD, Frederick H Neill, Lisa Lindesmith iD, Ralph S Baric iD, Amanda Brinkman, Ralph Braun, James Sherwood, Mary K Estes iD

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiad401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Robert L Atmar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Caliciviridae Infections, Norovirus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Takeda Vaccines, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A GII.2 outbreak in an efficacy study of a bivalent virus-like particle norovirus vaccine, TAK-214, in healthy US adults provided an opportunity to examine GII.4 homotypic vs GII.2 heterotypic responses to vaccination and infection. Three serologic assays—virus-like particle binding, histoblood group antigen blocking, and neutralizing—were performed for each genotype. Results were highly correlated within a genotype but not between genotypes. Although the vaccine provided protection from GII.2-associated disease, little GII.2-specific neutralization occurred after vaccination. Choice of antibody assay can affect assessments of human norovirus vaccine immunogenicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, NeutralizingAntibodies, ViralCaliciviridae InfectionsNorovirusViral VaccinesAdultFemaleHumansMaleMiddle AgedYoung AdultGastroenteritisGenotypeVaccines, Virus-Like Particle

Stichwörter der Autor:innen

binding antibodyhistoblood group antigen-blocking antibodyhuman norovirusneutralizing antibodyvaccine

Substanzen

Antibodies, NeutralizingAntibodies, ViralVaccines, Virus-Like ParticleViral Vaccines

Autor:innen und Institutionen

  • Department of Medicine.
  • Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
  • Department of Epidemiology, University of North Carolina, Chapel Hill.
  • Takeda Vaccines Inc, Cambridge, Massachusetts.
  • Takeda Pharmaceuticals International AG, Zurich, Switzerland.

ORCID-Profile: Robert L Atmar, Khalil Ettayebi, Sasirekha Ramani, Lisa Lindesmith, Ralph S Baric, Mary K Estes

Förderung

  • Takeda Vaccines, Inc

Zitieren

APA

Atmar, R. L., Ettayebi, K., Ramani, S., Neill, F. H., Lindesmith, L., Baric, R. S., Brinkman, A., Braun, R., Sherwood, J., & Estes, M. K. (2024). A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad401

Vancouver

Atmar RL, Ettayebi K, Ramani S, Neill FH, Lindesmith L, Baric RS, et al. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiad401

BibTeX
@article{Atmar2024,
  author = {Atmar, Robert L and Ettayebi, Khalil and Ramani, Sasirekha and Neill, Frederick H and Lindesmith, Lisa and Baric, Ralph S and Brinkman, Amanda and Braun, Ralph and Sherwood, James and Estes, Mary K},
  title = {A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiad401}
}
Kostenlos starten →